Details of the Drug

General Information of Drug (ID: DMY2AH1)

Drug Name
Aminophenazone
Synonyms
AMINOPYRINE; Amidazofen; Amidazophen; Amidazophene; Amidofebrin; Amidofen; Amidophen; Amidophenazone; Amidopyrazoline; Amidopyrin; Amidopyrine; Aminofenazone; Aminophenazon; Aminopyrin; Anafebrina; Brufaneuxol; Dereuma; Dimapyrin; Dimethylaminoantipyrine; Dimethylaminoazophene; Dimethylaminophenazone; Dipirin; Dipyrin; Dipyrine; Eufibron; Febrinina; Febron; Hyparon; Itamidone; Mamallet-A; Novamidon; Piramidon; Pirazon; Piridol; Piromidina; Polinalin; Pyradone; Pyramidon; Pyramidone; aminophenazone; 4-Dimethylaminoantipyrine; 58-15-1
Affected Organisms
Humans and other mammals
ATC Code
N02BB03: Aminophenazone
N02BB: Pyrazolones
N02B: OTHER ANALGESICS AND ANTIPYRETICS
N02: ANALGESICS
N: NERVOUS SYSTEM
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 231.29
Logarithm of the Partition Coefficient (xlogp) 1
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [1]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 247.0508 micromolar/kg/day [2]
Water Solubility
The ability of drug to dissolve in water is measured as 55.55 mg/mL [1]
Chemical Identifiers
Formula
C13H17N3O
IUPAC Name
4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one
Canonical SMILES
CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)C
InChI
RMMXTBMQSGEXHJ-UHFFFAOYSA-N
InChIKey
1S/C13H17N3O/c1-10-12(14(2)3)13(17)16(15(10)4)11-8-6-5-7-9-11/h5-9H,1-4H3
Cross-matching ID
PubChem CID
6009
ChEBI ID
CHEBI:160246
CAS Number
58-15-1
UNII
01704YP3MO
DrugBank ID
DB01424
INTEDE ID
DR0089

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [3]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [3]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [4]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [5]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [6]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [3]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [6]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [3]
Steroid 17-alpha-monooxygenase (CYP17A1) DEX2KIA CP17A_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Biotransformations [7]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Gene/Protein Processing [8]
Prostaglandin G/H synthase 1 (PTGS1) OTHCRLEC PGH1_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 BDDCS applied to over 900 drugs
2 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
3 Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
4 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
5 Inhibition of human hepatic cytochrome P450s and steroidogenic CYP17 by nonylphenol. Biol Pharm Bull. 2002 Feb;25(2):235-8.
6 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
7 Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
8 Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. Toxicol Lett. 2014 Jul 3;228(1):13-24. doi: 10.1016/j.toxlet.2014.04.005. Epub 2014 Apr 15.
9 Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention. J Pharmacol Exp Ther. 2005 Dec;315(3):1298-305.